Nycomed effect is negligible
Investors learnt this week that the long-awaited €4.2bn repayment to leveraged loan investors from private equity-owned Nycomed’s sale to trade buyer Takeda Pharmaceuticals would arrive on September 30, but market participants said the effect on fund demand would be minimal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
